SCHEMBL4847744

SCHEMBL4847744

O=C(O)c1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 3/20 0.72
CSF1R P07333 3/20 0.70
KDM4E B2RXH2 2/20 0.67
ROCK2 O75116 1/20 0.67
MAP4K4 O95819 1/20 0.67
LCK P06239 1/20 0.67
PIM1 P11309 1/20 0.67
RPS6KB1 P23443 1/20 0.67
CDK2 P24941 1/20 0.67
MAPK1 P28482 1/20 0.67
EPHA2 P29317 1/20 0.67
FLT3 P36888 1/20 0.67
FRK P42685 1/20 0.67
CLK2 P49760 1/20 0.67
GSK3A P49840 1/20 0.67
GSK3B P49841 1/20 0.67
LIMK1 P53667 1/20 0.67
STK3 Q13188 1/20 0.67
CAMK2B Q13554 1/20 0.67
CAMK2G Q13555 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4854389 0.99 MAP2 (0.71) MAP2CSF1RKDM4EROCK2MAP4K4
SCHEMBL4854377 0.90 CSF1R (0.69) MAP2CSF1RKDM4EROCK2MAP4K4
SCHEMBL6059495 0.89 MAP2 (0.74) MAP2CSF1RKDM4EROCK2MAP4K4
SCHEMBL30043560 0.89 MAP2 (0.74) MAP2CSF1RKDM4EROCK2MAP4K4
SCHEMBL16795037 0.87 MAP2 (0.59) MAP2CSF1RKDM4EROCK2MAP4K4
SCHEMBL14916827 0.86 CSF1R (0.77) MAP2CSF1RKDM4EROCK2MAP4K4
SCHEMBL42364 0.84 MAP2 (1.00) MAP2CSF1RKDM4EROCK2MAP4K4
SCHEMBL4851140 0.84 CSF1R (0.76) MAP2CSF1RKDM4EROCK2MAP4K4
SCHEMBL19952864 0.83 PADI4 (0.66) MAP2PADI4
SCHEMBL6493833 0.83 PADI4 (0.81) PADI4IKBKBCHUKAKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968360-B1 QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS CONVERGENE LLC (US) 2021-01-20 EP disclosed
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2020-07-21 US disclosed
US-20190345162-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2019-11-14 US disclosed
US-10266536-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2019-04-23 US disclosed
US-20180134715-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2018-05-17 US disclosed
US-9809599-B2 Aryl-quinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2017-11-07 US disclosed
US-9809599-B2 Aryl-quinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2017-11-07 US disclosed
US-9809599-B2 Aryl-quinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2017-11-07 US disclosed
US-9695179-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2017-07-04 US disclosed
CN-103906735-B Novel aryl-quinoline derivatives 霍夫曼-拉罗奇有限公司 2016-12-07 CN disclosed
US-20130116234-A1 ARYL-QUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-05-09 US disclosed
US-20130116234-A1 ARYL-QUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-05-09 US disclosed
US-20130116234-A1 ARYL-QUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-05-09 US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
CN-1867334-A Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2006-11-22 CN disclosed
EP-1660087-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed
WO-2005009967-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins BRPF3, BRD3, BRDT MAP2 323/4885CSF1R 3174/4885KDM4E 1194/4885
US-20130116234-A1 ARYL-QUINOLINE DERIVATIVES FABP1, FABP4, FABP5 MAP2 1468/4885CSF1R 267/4885KDM4E 2685/4885
US-20190345162-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins BRPF3, BRD3, BRDT MAP2 323/4885CSF1R 3174/4885KDM4E 1194/4885
US-10266536-B2 Methods and compositions for inhibition of bromodomain-containing proteins BRPF3, BRD3, BRDT MAP2 323/4885CSF1R 3174/4885KDM4E 1194/4885
US-20180134715-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins BRPF3, BRD3, BRDT MAP2 323/4885CSF1R 3174/4885KDM4E 1194/4885
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase FLT3, ABL1, FES MAP2 304/4885CSF1R 192/4885KDM4E 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.